Novel Growth Factor Allograft Used to Support Interbody Fusion with MI-TLIF Procedures

Introduction: A novel growth factor allograft shown to provide the complete growth factor payload provided by the donor tissue was utilized to support interbody fusion with patients requiring minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) procedures.

Methods: An Institutional Review Board granted a waiver to retrospectively assess fusion results for patients receiving novel growth factors in supporting MI-TLIF procedures. Radiology produced during standard post-surgical follow-up was de-identified and independently reviewed by an accredited Radiologist for the state of fusion according to Brantigan, Steffee and Fraser criteria.

Results: At three months, 72 of 104 (69.2%) levels assessed were deemed to be fully fused, at six months 87 of 116 (75.0%) levels assessed were deemed to be fused, at twelve months 107 of 113 (94.7%) levels assessed were deemed to be fused, at eighteen months 107 of 109 (98.2%) levels assessed were deemed to be fused and ultimately at twenty-one months all 108 of 108 (100%) levels reviewed were deemed to be fully fused.

Conclusion: Novel growth factor allograft used to support MI-TLIF procedures provides a safe and effective alternative to supporting healthy bony remodeling desired with interbody fusion.